Nuvation Bio NUVB Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -105%+234pp | -338.7%+532pp | -871%+694pp | -1,564.9%+4,198pp | -5,762.8%+1,765pp | |
| Net margin | -102.1%+223pp | -325.3%+488pp | -813.1%+600pp | -1,413.4%+4,121pp | -5,534.2%+1,680pp | |
| EBITDA margin | -103.6%+232pp | -336%+530pp | -865.7%+692pp | -1,557.6%+4,197pp | -5,754.3%+1,764pp | |
| Free cash flow margin | -93.5%+195pp | -288.4%+452pp | -740.2%+433pp | -1,173.2%+263pp | -1,436.4%+220pp | |
| Returns | ||||||
| Return on equity | -39.5%+13.7pp | -53.2%-0.7pp | -52.5%+11.9pp | -64.4%+55.3pp | -119.7%-13.4pp | |
| Return on assets | -26.5%+9.6pp | -36%+1.0pp | -37.1%-4.4pp | -32.7%+77.0pp | -109.7%-11.9pp | |
| Return on invested capital | -47.4%+19.6pp | -67%-6.4pp | -60.6%+46.3pp | -106.9%+26.6pp | -133.5%-15.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.1× | 0.1×+0.1× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 7.4×+0.5× | 7×-1.5× | 8.5×-0.9× | 9.4×+0.4× | 9×0.0× | |
| Quick ratio | 7.2×+0.4× | 6.8×-1.6× | 8.4×-1.0× | 9.4×+0.4× | 9×0.0× | |
| Cash ratio | 1.6×-0.4× | 2×+0.5× | 1.5×-2.3× | 3.7×+2.8× | 0.9×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | 0×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | 0×0.0× | |
| Interest coverage | -7.4×+8.2× | -15.6×+17.2× | -32.8×+296× | -328.4×+1,270× | -1,598.6×+139× | |
| Per Share | ||||||
| Book value per share | $0.85-5.4% | $0.90-6.0% | $0.95-13.0% | $1.09-11.7% | $1.24-28.2% | |
| Valuation | ||||||
| Market capitalization | $1.49B-51.5% | $3.07B+143% | $1.27B+81.6% | $697.54M+17.0% | $596.07M-33.4% | |
| Enterprise value | $1.42B-52.0% | $2.97B+142% | $1.23B+141% | $507.33M-9.3% | $559.51M-35.6% | |
| Price / sales | 10.4×-38.4× | 48.8×+1.5× | 47.3×-1.2× | 48.6×-5.8× | 54.4×-59.3× | |
| Price / book | 4.7×-5.4× | 10×+6.2× | 3.9×+2.0× | 1.9×+0.4× | 1.4×-0.5× | |
| EV / sales | 9.9×-37.2× | 47.1×+1.3× | 45.8×+10.5× | 35.3×-15.7× | 51.1×-59.2× | |
| Free cash flow yield | -9%-3.1pp | -5.9%+9.7pp | -15.6%+8.5pp | -24.1%+2.3pp | -26.4%-11.8pp | |
| Earnings yield | -9.8%-3.1pp | -6.7%+10.5pp | -17.2%+11.9pp | -29.1%+72.6pp | -101.7%-38.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nuvation Bio's profit margins?
- Nuvation Bio (NUVB) runs a 54.3% gross margin and a -105.0% operating margin, with a -102.1% net margin.
- Where do Nuvation Bio's ratios come from?
- Every ratio is computed from Nuvation Bio's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.